Paratek Pharmaceuticals, Inc.

NasdaqGM:PRTK Rapport sur les actions

Capitalisation boursière : US$127.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Paratek Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Paratek Pharmaceuticals' CEO is Evan Loh, appointed in Jun 2019, has a tenure of 4.25 years. total yearly compensation is $2.04M, comprised of 31.8% salary and 68.2% bonuses, including company stock and options. directly owns 1.87% of the company’s shares, worth $2.38M. The average tenure of the management team and the board of directors is 4.3 years and 8.9 years respectively.

Informations clés

Evan Loh

Directeur général

US$2.0m

Rémunération totale

Pourcentage du salaire du PDG31.8%
Durée du mandat du directeur général4.3yrs
Propriété du PDG1.9%
Durée moyenne d'occupation des postes de direction4.3yrs
Durée moyenne du mandat des membres du conseil d'administration8.9yrs

Mises à jour récentes de la gestion

Recent updates

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Apr 17
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Paratek Pharmaceuticals: Patience Is Wearing Thin

Aug 24

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Aug 03

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

Jan 03

The Play On Paratek Pharmaceuticals

Oct 18

Peeking Back In On Paratek Pharmaceuticals

Aug 07

Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial

Jun 16

Paratek shares rise after FDA approves NUZYRA oral only dosing regimen

Jun 01

Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business

Apr 27

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Mar 01
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Feb 01
Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment

Jan 04

Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale

Dec 01

Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Analyse de la rémunération des PDG

Comment la rémunération de Evan Loh a-t-elle évolué par rapport aux bénéfices de Paratek Pharmaceuticals?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2023n/an/a

-US$63m

Mar 31 2023n/an/a

-US$66m

Dec 31 2022US$2mUS$650k

-US$64m

Sep 30 2022n/an/a

-US$89m

Jun 30 2022n/an/a

-US$86m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$4mUS$600k

-US$59m

Sep 30 2021n/an/a

-US$52m

Jun 30 2021n/an/a

-US$54m

Mar 31 2021n/an/a

-US$87m

Dec 31 2020US$2mUS$575k

-US$97m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$111m

Mar 31 2020n/an/a

-US$121m

Dec 31 2019US$2mUS$520k

-US$129m

Sep 30 2019n/an/a

-US$124m

Jun 30 2019n/an/a

-US$124m

Mar 31 2019n/an/a

-US$120m

Dec 31 2018US$2mUS$480k

-US$112m

Sep 30 2018n/an/a

-US$111m

Jun 30 2018n/an/a

-US$101m

Mar 31 2018n/an/a

-US$89m

Dec 31 2017US$3mUS$450k

-US$89m

Sep 30 2017n/an/a

-US$94m

Jun 30 2017n/an/a

-US$96m

Mar 31 2017n/an/a

-US$108m

Dec 31 2016US$1mUS$415k

-US$112m

Rémunération vs marché: Evan's total compensation ($USD2.04M) is above average for companies of similar size in the US market ($USD764.66K).

Rémunération et revenus: Evan's compensation has been consistent with company performance over the past year.

PDG

Evan Loh (64 yo)

4.3yrs

Titularisation

US$2,042,511

Compensation

Dr. Evan Loh, M.D., FACC, FAHA, has been the Chief Executive Officer of Paratek Pharmaceuticals, Inc. since June 25, 2019. Dr. Loh served as Independent Director at Windtree Therapeutics, Inc. since Februa...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Michael Bigham
Executive Chairman8.9yrsUS$1.73m1.93%
$ 2.5m
Evan Loh
CEO & Director4.3yrsUS$2.04m1.87%
$ 2.4m
Adam Woodrow
President & Chief Commercial Officer4.3yrsUS$1.15m1.09%
$ 1.4m
Sarah Higgins
VP of Finance8.5yrspas de donnéespas de données
William Haskel
Senior VP8.3yrsUS$1.25m0.62%
$ 797.8k
Jonathan Light
Deputy General Counsel & Chief Compliance Officer6.1yrspas de donnéespas de données
Karen McGrath
Chief People Officer4.2yrspas de donnéespas de données
Randall Brenner
Chief Development & Regulatory Officer4.3yrspas de données0.58%
$ 735.2k

4.3yrs

Durée moyenne de l'emploi

58.5yo

Âge moyen

Gestion expérimentée: PRTK's management team is considered experienced (4.3 years average tenure).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Michael Bigham
Executive Chairman8.9yrsUS$1.73m1.93%
$ 2.5m
Evan Loh
CEO & Director11.3yrsUS$2.04m1.87%
$ 2.4m
Jeffrey Stein
Lead Independent Director8.9yrsUS$147.80k0.097%
$ 124.0k
Thomas Dietz
Independent Outside Director8.9yrsUS$150.30k0.087%
$ 111.5k
Kristine Peterson
Independent Outside Director7.5yrsUS$137.80k0.10%
$ 131.6k
Timothy Franson
Independent Outside Director8.2yrsUS$135.30k0.10%
$ 131.6k
Robert Radie
Independent Outside Director8.9yrsUS$140.30k0.091%
$ 116.5k
Rolf Hoffmann
Independent Director5.4yrsUS$127.80k0.11%
$ 142.7k
Minnie Baylor-Henry
Independent Director2.3yrsUS$132.80k0.068%
$ 87.4k

8.9yrs

Durée moyenne de l'emploi

64yo

Âge moyen

Conseil d'administration expérimenté: PRTK's board of directors are considered experienced (8.9 years average tenure).